Co-Carriage Rates of Vancomycin-Resistant Enterococcus and Extended-Spectrum Beta-Lactamase-Producing Bacteria Among a Cohort of Intensive Care Unit Patients: Implications for an Active Surveillance Program

Abstract Objective: To assess the co-colonization rates of extended-spectrum beta-lactamase (ESBL)-producing bacteria and vancomycin-resistant Enterococcus (VRE) obtained on active surveillance cultures. Design: Prospective cohort study. Setting: Medical and surgical intensive care units (ICUs) of a tertiary-care hospital. Patients: Patients admitted between September 2001 and November 2002 to the medical and surgical ICUs at the University of Maryland Medical System had active surveillance perirectal cultures performed. Samples were concurrently processed for VRE and ESBL-producing bacteria. Results: Of 1,362 patients who had active surveillance cultures on admission, 136 (10%) were colonized with VRE. Among these, 15 (positive predictive value, 11%) were co-colonized with ESBL. Among the 1,226 who were VRE negative, 1,209 were also ESBL negative (negative predictive value, 99%). Among the 1,362 who had active surveillance cultures on admission, 32 (2%) were colonized with ESBL. Among these, 15 (47%) were co-colonized with VRE. Of the 32 patients colonized with ESBL, 10 (31%) had positive clinical cultures for ESBL on the same hospital admission. For these 10 patients, the surveillance cultures were positive an average of 2.7 days earlier than the clinical cultures. Conclusions: Patients who are colonized with VRE can also be co-colonized with other antibiotic-resistant bacteria such as ESBL-producing bacteria. Our study is the first to measure co-colonization rates of VRE and ESBL-producing bacteria. Isolating VRE-colonized patients would isolate 47% of the ESBL-colonized patients without the need for further testing. Hence, active surveillance for VRE should also theoretically diminish the amount of patient-to-patient transmission of ESBL-producing bacteria.

[1]  G. Jacoby Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. , 1997, Infectious disease clinics of North America.

[2]  G. Jacoby EXTENDED-SPECTRUM β-LACTAMASES AND OTHER ENZYMES PROVIDING RESISTANCE TO OXYIMINO-β-LACTAMS , 1997 .

[3]  S. Mitsuhashi,et al.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.

[4]  Carlene A. Muto,et al.  Cost-Effectiveness of Perirectal Surveillance Cultures for Controlling Vancomycin-Resistant Enterococcus , 2002, Infection Control & Hospital Epidemiology.

[5]  M. Edmond Cost-Effectiveness of Perirectal Surveillance Cultures for Controlling Vancomycin-Resistant Enterococcus , 2003, Infection Control & Hospital Epidemiology.

[6]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Carlene A. Muto,et al.  SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of Staphylococcus aureus and Enterococcus , 2003, Infection Control & Hospital Epidemiology.

[8]  E. Jochimsen,et al.  Control of Vancomycin-Resistant Enterococci at a Community Hospital: Efficacy of Patient and Staff Cohorting , 1999, Infection Control & Hospital Epidemiology.

[9]  M. Pfaller,et al.  The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. , 1995, American journal of infection control.

[10]  J. Quinn,et al.  Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae , 1989, Antimicrobial Agents and Chemotherapy.

[11]  D. Maki,et al.  The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida , 2002, Annals of Internal Medicine.

[12]  R A Weinstein,et al.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. , 1999, JAMA.

[13]  J. Morris,et al.  The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. , 2002, American journal of infection control.

[14]  S. Chevret,et al.  Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Bradford Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[16]  Natural history of colonization with vancomycin-resistant Enterococcus faecium. , 1995, Infection control and hospital epidemiology.

[17]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[18]  M. Samore,et al.  Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. , 1999, Archives of internal medicine.

[19]  G. Wormser,et al.  Infection-Control Measures Reduce Transmission of Vancomycin-Resistant Enterococci in an Endemic Setting , 1999, Annals of Internal Medicine.

[20]  P. Murray,et al.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis , 1989, Antimicrobial Agents and Chemotherapy.

[21]  A. Sohn,et al.  Reality Check: Should We Try to Detect and Isolate Vancomycin-Resistant Enterococci Patients? , 2001, Infection Control & Hospital Epidemiology.

[22]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Ariza,et al.  Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. , 1997, The Journal of hospital infection.

[24]  W. Trick,et al.  Control of vancomycin-resistant enterococcus in health care facilities in a region. , 2001, The New England journal of medicine.